Jeffrey Alan Sosman

← Back to Northwestern University

ORCID

Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.

Selected research works

Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.

1. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

   2010 · 15,151 citations

2. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

   2012 · 12,603 citations

3. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

   2011 · 7,716 citations

4. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

   2015 · 5,797 citations

5. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

   2017 · 5,342 citations

6. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

   2014 · 5,222 citations

7. Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma

   2007 · 3,647 citations

8. Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

   2010 · 3,561 citations

9. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

   2016 · 3,432 citations

10. Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

    2012 · 2,810 citations

11. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors

    2018 · 2,658 citations

12. Fulminant Myocarditis with Combination Immune Checkpoint Blockade

    2016 · 2,288 citations

13. Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

    2014 · 2,218 citations

14. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

    2010 · 2,192 citations

15. Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

    2009 · 2,181 citations

16. Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

    2012 · 2,158 citations

17. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

    2010 · 1,831 citations

18. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

    2015 · 1,572 citations

19. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

    2011 · 1,446 citations

20. Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K

    2010 · 1,259 citations

21. Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

    2015 · 1,177 citations

22. RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors

    2012 · 1,038 citations

23. Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

    2014 · 979 citations

24. Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy

    2013 · 978 citations

25. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis

    2018 · 931 citations

← Return to the university profile